|
TABLE OF CONTENTS
Introduction
Faculty
Metabolic and Morphologic Complications of HIV and HAART
Metabolic and Morphologic Complications of HIV and HAART: One Syndrome or Many?
HIV Wasting: Incidence in the HAART Era - Nutrition for Healthy Living (NFHL) Study
HIV Wasting: Incidence in the NFHL Cohort (N=466)
HIV Wasting: Weight Loss in the NFHL Cohort (N=497)
HIV Wasting: Relationship of Incidence to HAART Use in the NFHL Cohort (N=633)
HIV Wasting: Effect of HAART
HIV Wasting: Loss of Lean Body Mass (LBM) and Fat Mass (FM)
HIV Wasting: Is It Wasting or Fat Atrophy?
HIV Wasting: Etiology of Weight Loss
HIV Wasting: Effects
HIV Wasting: Definition
HIV Wasting: Initial Patient Evaluation
HIV Wasting: Initial Patient Evaluation – Suggested Questions
HIV Wasting: Initial Patient Evaluation – Body Composition Measurements
HIV Wasting: Bioelectrical Impedance Analysis (BIA)
HIV Wasting: BIA Studies in HIV-Infected Patients
HIV Wasting: Other Body Composition Techniques
HIV Wasting: Validation and Advantages of BIA
HIV Wasting: Initial Patient Evaluation – Laboratory Tests
HIV Wasting: Follow-Up Visit
HIV Wasting: General Patient Management
HIV Wasting: Interventions and Treatment
HIV Wasting: Growth Hormone rhGH[m] (Serostim®)1,2
HIV Wasting: Initial Therapy with rhGH[m] (Serostim®)
HIV Wasting: Placebo-Controlled Trial of rhGH[m] (Serostim®)
HIV Wasting: Change in Body Composition with rhGH[m] (Serostim®) Therapy
HIV Wasting: Testosterone for Hypogonadal Patients1-4
HIV Wasting: Management and Treatment Algorithm
HIV Wasting: Anabolic Agents for Non-Hypogonadal Patients1-5
HIV Wasting: Nandrolone (Deca Durabolin®)
HIV Wasting: Oxandrolone (Oxandrin®)
HIV Wasting: Anabolic Agents1-6
HIV Wasting: Appetite Stimulants for Anorexia1-6
HIV Wasting: Dronabinol (Marinol®)1, 2
HIV Wasting: Megestrol Acetate (Megace®)
HIV Wasting: Megestrol Acetate (Megace®) – Study Results
HIV Wasting: Adjunctive Treatments and Interventions
HIV Wasting: Progressive Resistance Exercise (PRE)
HIV Wasting: Post-Treatment Visits – Every 3 Months
HIV Wasting: Expected Clinical Outcomes
HIV Wasting: Summary and Conclusions
Morphologic Changes: Definitions
Morphologic Changes: Implications
Morphologic Changes: Prevalence
Morphologic Changes: Predictors –The HIV Outpatient Study (HOPS)
Morphologic Changes: Gender Differences
Morphologic Changes: Role of PIs – Hypothesis
Morphologic Changes: Risk of Fat Loss/Accumulation with PIs
Morphologic Changes: Risk of Fat Loss/Accumulation with PIs – Results
Morphologic Changes: Risk of Fat Loss/Accumulation with PIs – Progression to Lipodystrophy
Morphologic Changes: Risk of Fat Loss/Accumulation with PIs – Factors Associated with Progression
Morphologic Changes: Role of NRTIs – Hypothesis
Morphologic Changes: Diagnosis and Monitoring
Morphologic Changes: Management Approaches
Morphologic Changes: Switching Antiretroviral Therapy
Morphologic Changes: Exercise
Morphologic Changes:
Recombinant Human Growth Hormone (Serostim®)
Morphologic Changes: Other Studies of Growth Hormone Therapy for Lipodystrophy
Morphologic Changes: Metformin Therapy for Lipodystrophy
Morphologic Changes: Metformin – Mean Change in Weight and Waist Circumference
Morphologic Changes: Summary and Conclusions
Dyslipidemia: Characteristics
Dyslipidemia: Increased Risk of Cardiovascular Disease in HIV
Dyslipidemia: Evaluation of Serum Lipids
Dyslipidemia: Indications for Intervention – Hypercholesterolemia (National Cholesterol Education Program)
Dyslipidemia: Indications for Intervention – Hypertriglyceridemia
Dyslipidemia: Management Approaches
Dyslipidemia: Drug Therapies
Dyslipidemia: HMG-CoA Reductase Inhibitors (Statins)
Dyslipidemia: Fibrates
Dyslipidemia: Antiretroviral Switching Strategies
Dyslipidemia: Summary and Conclusions
Glucose Metabolism: PI-Associated History
Glucose Metabolism: Reported Incidence
Glucose Metabolism: Insulin Resistance
Glucose Metabolism: Mechanisms of Insulin Resistance
Glucose Metabolism: Evaluation and Diagnosis
Glucose Metabolism: Diagnostic Criteria for Diabetes
Glucose Metabolism: Diagnostic Criteria for Impaired Glucose Tolerance
Glucose Metabolism: Impact of Body Composition Changes
Glucose Metabolism: Fasting and Two-Hour Glucose Levels
Glucose Metabolism: Fasting and Two-Hour Insulin Levels
Glucose Metabolism:
Metabolic Profile in the HIV Lipodystrophy Syndrome
Glucose Metabolism: Management Strategies
Glucose Metabolism: Drug Therapies
Glucose Metabolism: Metformin – Impact on PAI-1 and tPA Antigen Levels
Glucose Metabolism: Metformin – Correlation Between Change in Insulin and tPA Levels
Glucose Metabolism: Metformin – Impact on PAI-1 and tPA Antigen Levels Results
Glucose Metabolism: Summary and Conclusions
Lactic Acidosis: Symptoms and Laboratory Findings
Lactic Acidosis: Defining the Syndrome
Lactic Acidosis: NRTIs and Pathogenesis
Lactic Acidosis: In Vitro Effects of NRTIs
Lactic Acidosis: Frequency
Lactic Acidosis: Clinical Features
Lactic Acidosis: Outcomes and Risk Factors
Lactic Acidosis: Treatment1-4
Lactic Acidosis: Summary and Conclusions
Hyperlactatemia: Defining the Syndrome
Hyperlactatemia: Prevalence
Hyperlactatemia: Incidence in Patients Receiving NRTIs
Hyperlactatemia: Incidence Rate for Specific NRTIs
Hyperlactatemia: Relative Risk Compared with ZDV/3TC-Containing Regimens
Hyperlactatemia: Switching d4T for ZDV or ABC in Patients with Fat Wasting – Effect on Lactate
Hyperlactatemia: Summary and Conclusions
Abacavir Hypersensitivity Reaction: Symptoms
Abacavir Hypersensitivity Reaction: Risk with Therapy Interruptions
Abacavir Hypersensitivity Reaction: Study Results
Abacavir Hypersensitivity Reaction: Conclusions
Neuropathy: Risk with Hydroxyurea (HU)
Neuropathy: Incidence Rates and Relative Risks
Hepatotoxicity: Risk with NNRTIs
Hepatotoxicity: Risk with NNRTIs and Hepatitis
Hepatotoxicity: Risk with NRTIs and Hydroxyurea (HU)
Toxicities of HAART: Summary and Conclusions
Bone Disorders: Osteopenia and Osteoporosis1,2
Bone Disorders: Osteoporosis – Classification
Bone Disorders: Osteoporosis – Associated Disorders
Bone Disorders: Osteoporosis – Diagnosis and Treatment
Bone Disorders: Prevalence and Association with Antiretrovirals
Bone Disorders: Disturbed Bone Formation and Resorption
Bone Disorders: Influence of HAART on Bone Remodeling
Bone Disorders: Avascular Necrosis (Osteonecrosis)
Bone Disorders: Avascular Necrosis – Diagnosis and Treatment
Bone Disorders: Avascular Necrosis in HIV Infection
Bone Disorders: Summary and Conclusions
|